Literature DB >> 15252822

Subjective and polysomnographic effects of milnacipran on sleep in depressed patients.

Patrick Lemoine1, Thierry Faivre.   

Abstract

The effects of milnacipran (50 mg bid) on sleep patterns of eight depressed inpatients, treated for 4 weeks, were studied during the initial (days 1-3) and terminal (days 26-28) treatment periods and compared with those obtained from three sleep recordings performed just prior to the initiation of the treatment. The clinical evolution of patients was evaluated weekly using the MADRS depression scale and the Spiegel and Norris sleep scales. Clinical improvement, shown by a mean reduction of 58% in MADRS scale scores, was accompanied by an improvement of disturbed sleep parameters. From the beginning of treatment, there was an increase in the total duration of sleep and stage II sleep, a decrease in sleep latency and an increase in sleep efficiency. Total REM sleep was not modified although, since there was an increase in total sleep time, the percent REM sleep was significantly reduced. REM latency was increased early in the study, an effect classically associated with antidepressant treatment. This study suggests that milnacipran improves disturbed sleep parameters in depressed patients without any additional disturbance at the onset of treatment. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252822     DOI: 10.1002/hup.600

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

1.  Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome.

Authors:  Todd J Swick
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-08       Impact factor: 5.346

Review 2.  Antidepressants and sleep: a qualitative review of the literature.

Authors:  Sue Wilson; Spilios Argyropoulos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study.

Authors:  Mansoor Ahmed; Rozina Aamir; Zahra Jishi; Martin B Scharf
Journal:  J Clin Sleep Med       Date:  2016-01       Impact factor: 4.062

4.  Improvement of the noradrenergic symptom cluster following treatment with milnacipran.

Authors:  Siegfried Kasper; Diana Meshkat; Alexandra Kutzelnigg
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-31       Impact factor: 2.570

Review 5.  Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment.

Authors:  Peter Hutka; Michaela Krivosova; Zuzana Muchova; Ingrid Tonhajzerova; Andrea Hamrakova; Zuzana Mlyncekova; Juraj Mokry; Igor Ondrejka
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

Review 6.  The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression.

Authors:  Yi-Qun Wang; Rui Li; Meng-Qi Zhang; Ze Zhang; Wei-Min Qu; Zhi-Li Huang
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.